SPR Therapeutics Appoints Michael P. Chuisano to B

CLEVELAND, March 21, 2017 (GLOBE NEWSWIRE) -- SPR Therapeutics, LLC, a private medical device company that has developed a novel, evidence-based neurostimulation platform for chronic and acute pain, announced that it has appointed Michael P. Chuisano, former Vice President and Chief Operating Officer of Johnson & Johnson Innovation-JJDC, Inc.(JJDC), the venture subsidiary of Johnson & Johnson, to its board of directors effective immediately.   

“Mike is a significant addition to the SPR board, and we are pleased to have his talents and experience as demonstrated across his successes at Johnson & Johnson as we develop and commercialize our novel, pain-management therapy through the SPRINT™ PNS System,” said Maria Bennett, Founder, President and CEO.  “I’m confident that his passion for identifying and advancing novel technologies to enhance patient lives, in a very complex healthcare system, will be of value to SPR.  His experience at JJDC, as well as his service as a director on numerous JJDC portfolio companies, will be of significant value to our board, and will help to shape the strategic direction of the company, while improving the quality of life for patients afflicted with debilitating acute and chronic pain.”

“It is an honor to join an organization, that under Maria’s leadership was founded on deep science and clinical validation, and is now positioned to be an emerging leader in the pain management field,” said Chuisano.  “I believe their novel, less-invasive peripheral nerve stimulation technology and approach incorporated into the SPRINT™ PNS System has the potential to significantly advance the treatment of chronic and acute pain without the use of opioids, and as it does not require permanent implantation, should further reduce invasiveness, risk and cost.” 

Chuisano’s career spans over three decades at Johnson & Johnson, and brings diversified business experience from across the consumer health, medical device and pharmaceuticals businesses of Johnson & Johnson.  In 2012, he was appointed to his most recent position as Vice President and Chief Operating Officer for JJDC, and led the consumer venture investing portfolio while supporting several medical device investments.  While at JJDC, he served on more than 10 venture-backed private company boards, and led over $200 million in venture capital investments.  Chuisano previously served as vice president of business development for Johnson & Johnson’s Corporate Development Group, with prior experiences including several leadership positions in Johnson & Johnson’s Pharmaceuticals Group and the medical device group businesses of Ethicon Endo-Surgery, Inc. and Ethicon, Inc.

Chuisano holds a Master of Business Administration (MBA) from Fairleigh Dickinson University, and a Bachelor of Science degree in industrial engineering from the University at Buffalo, School of Engineering and Applied Science. 

About SPR Therapeutics

SPR Therapeutics, LLC ( www.sprtherapeutics.com ) is a private company headquartered in Cleveland.  The company is commercializing its SPRINT™ technology which provides opioid-free, peripheral nerve stimulation for the relief of chronic and acute pain, and is advancing additional clinical trials to treat low back pain and pain following total knee replacement.  The SPR-patented SPRINT technology received FDA clearance for commercial use in the US.

SPR Therapeutics, LLC .  22901 Millcreek Blvd, Suite 110, Cleveland, OH 44122. Phone (844) 378-9108  Fax (216) 803-0777  www.sprtherapeutics.com

SPR Contact: Mark Stultz   Senior Vice President mstultz@sprtherapeutics.com 612.770.0390 FOR MEDIA QUERIES, Contact: Tracey Sawicki Frontcourt PR tracey@frontcourtgroup.com 917-297-0574